ARTICLE | Emerging Company Profile
Delfi: Making early cancer detection tests more accessible
Diagnostic company aims for early 2023 early cancer detection test launch with $225M B round
July 18, 2022 11:05 PM UTC
With an additional $225 million from a series B round, Delfi is working to make liquid biopsy tests for early detection of cancer less expensive and more accessible. It’s hoping to bring the technology to the market early next year.
DFJ Growth led the round, announced Monday, with Eli Lilly and Co. (NYSE:LLY) becoming the company’s second strategic investor after Illumina Ventures, which invested in the company’s $100 million series A financing in January 2021. ...